Author + information
- Received August 13, 2009
- Revision received November 9, 2009
- Accepted December 14, 2009
- Published online June 8, 2010.
- James H.F. Rudd, MD, PhD*,* (, )
- Jagat Narula, MD, PhD†,
- H. William Strauss, MD‡,
- Renu Virmani, MD§,
- Josef Machac, MD∥,
- Mike Klimas, PhD#,
- Nobuhiro Tahara, MD, PhD**,
- Valentin Fuster, MD, PhD¶,
- Elizabeth A. Warburton, MD, DM*,
- Zahi A. Fayad, PhD¶ and
- Ahmed A. Tawakol, MD††
- ↵*Reprint requests and correspondence:
Dr. James H. F. Rudd, Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Box 110, ACCI, Hills Road, Cambridge CB2 2QQ, England
Inflammation is a determinant of atherosclerotic plaque rupture, the event leading to most myocardial infarctions and strokes. Although conventional imaging techniques identify the site and severity of luminal stenosis, the inflammatory status of the plaque is not addressed. Positron emission tomography imaging of atherosclerosis using the metabolic marker fluorodeoxyglucose allows quantification of arterial inflammation across multiple vessels. This review sets out the background and current and potential future applications of this emerging biomarker of cardiovascular risk, along with its limitations.
Work described in this article was supported by the NIHR Cambridge Biomedical Centerand the British Heart Foundation. Dr. Rudd is an advisory board member for Roche and BG Medicine, has received research funding from GlaxoSmithKline, has received consulting fees from VIA Pharmaceuticals, and has received fees from WebMD for providing conference coverage on their website. Dr. Machac has relationships with Phillips, GE Healthcare, and Bristol-Myers Squibb. Dr. Klimas is an employee of Merck and Co. Dr. Fuster is the Chair of the HRP Study with BG Medicine. Joseph L. Wu, MD, PhD, served as Guest Editor for this paper.
- Received August 13, 2009.
- Revision received November 9, 2009.
- Accepted December 14, 2009.
- American College of Cardiology Foundation
- Rationale for FDG PET Atherosclerosis Imaging: Plaque Inflammation
- Uptake of FDG Into Plaque Cells
- Review of FDG PET Atherosclerosis Imaging: Pre-Clinical Studies
- FDG PET Atherosclerosis Imaging: Clinical Studies
- Coronary Artery FDG PET Imaging
- Reproducibility of FDG PET Atherosclerosis Imaging
- Relationship of FDG Uptake to Vascular Events
- Can Arterial FDG Uptake Be Modified With Therapy?